Hood River Capital Management LLC Has $105.33 Million Stake in Insmed Incorporated (NASDAQ:INSM)

Hood River Capital Management LLC grew its stake in Insmed Incorporated (NASDAQ:INSM) by 3.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,525,628 shares of the biopharmaceutical company’s stock after acquiring an additional 53,073 shares during the period. Insmed accounts for 1.6% of Hood River Capital Management LLC’s holdings, making the stock its 10th biggest holding. Hood River Capital Management LLC’s holdings in Insmed were worth $105,329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new position in Insmed during the 3rd quarter worth approximately $248,000. Tidal Investments LLC grew its holdings in shares of Insmed by 447.0% in the third quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company’s stock valued at $1,759,000 after purchasing an additional 19,696 shares during the period. Principal Financial Group Inc. grew its position in Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after acquiring an additional 214,130 shares during the period. Everence Capital Management Inc. acquired a new position in Insmed during the fourth quarter worth $352,000. Finally, Harbor Capital Advisors Inc. grew its position in Insmed by 237.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company’s stock valued at $4,115,000 after acquiring an additional 41,918 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently commented on INSM. UBS Group lifted their target price on Insmed from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Guggenheim reissued a “buy” rating and issued a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. JPMorgan Chase & Co. boosted their price objective on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Stifel Nicolaus decreased their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $94.00.

Insmed Trading Up 2.5 %

Shares of INSM stock opened at $71.24 on Wednesday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The stock has a market cap of $12.95 billion, a P/E ratio of -12.74 and a beta of 1.07. The stock has a 50 day simple moving average of $74.99 and a 200 day simple moving average of $73.58.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. On average, research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In related news, insider Martina M.D. Flammer sold 33,055 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the transaction, the insider now owns 138,053 shares of the company’s stock, valued at $11,168,487.70. This represents a 19.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 6,830 shares of the stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the sale, the chief executive officer now directly owns 233,924 shares of the company’s stock, valued at approximately $16,412,107.84. This trade represents a 2.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 471,797 shares of company stock worth $37,621,239 in the last quarter. 3.00% of the stock is currently owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.